Business
Theralase Granted US Patent for Multiwavelength Photodynamic Therapy
TORONTO, ON / ACCESSWIRE / January 27, 2020 / Theralase® Technologies Inc. (" Therala...
About this update from Theralase Technologies Inc.
[{"type":"text","content":"Theralase Granted US Patent for Multiwavelength Photodynamic TherapyTORONTO, ON / ACCESSWIRE / January 27, 2020 / Theralase® Technologies Inc. (\"Theralase\" or the \"Company\") (TSXV:TLT)(OTCQB:TLTFF), a clinical stage pharmaceutical company dedicated to the research and development of light activated Photo Dynamic Compounds (\"PDC\") and their associated drug formulations intended to safely and effectively destroy various cancers, is pleased to announce that the Company has been granted a U.S. Patent for Multiwavelength PhotoDynamic Therapy (\"PDT\") technology.The U.S. patent entitled \"Apparatus and Method for Multiwavelength Photodynamic Therapy\" allows Theralase to use various laser wavelengths in the activation of PhotoDynamic Compounds (\"PDC\") in cancerous tumours. The advantage is that a large or deep seated tumour may be only partially destroyed with laser of a particular wavelength, but then fully destroyed by employing one or two additional laser wavelengths, as different laser wavelengths are able to penetrate to different tissue depths. This would be especially important for cancers, such as Glio Blastoma Multiforme (\"GBM\") or Non-Small Cell Lung Cancer (\"NSCLC\").Dr. Arkady Mandel M.D., Ph.D., D.Sc, Chief Scientific Officer of Theralase stated, \"Theralase specializes in the development of safe, effective and targeted cancer therapy. This U.S. patent increases Company value by protecting optimized PDT technology which would be effective in large or difficult to reach tumours that are not accessible by certain laser wavelengths. Theralase continues to develop a comprehensive intellectual property portfolio, which strengthens Theralase's position in the global oncology market.\"The global market for oncology therapeutic medicines will reach as high as $200 billion by 2022, with the U.S. market reaching as high as $100 billion by 2022, averaging 12-15% growth1.About Theralase® Technologies Inc.Theralase® is a clinical stage pharmaceutical company dedicated to the research and development of light activated Photo Dynamic Compounds and their associated drug formulations intended to safely and effectively destroy various cancers.Additional information is available at www.theralase.com and www.sedar.com1 Coherent Market Insights. https://www.marketwatch.com/press-release/global-oncology-drugs-market-...